Gitte Aabo will step down as President and CEO after 27 years in the company, and 11 of these as CEO, and the Board of Directors has appointed Catherine Mazzacco
The company announces the addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors.
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
Nordic Life Science
The latest clinical trials
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful improvement in
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa. All participants have now been enrolled and the last travellers
The topline results from the 12-month follow-up review of the Phase 1 Lymfactin trial in breast cancer-associated lymphedema has been announced. The study’s data monitoring committee (DMC) concluded that the
The Permanent Secretary at Ministry of Health Dr Kennedy Malama together with the Swedish Ambassador Henrik Cederin, Dr Izukanji Sikazwe CEO at Centre for Infectious Disease Research in Zambia (CIDRZ)
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019
A Phase II trial has demonstrated that Fasenra (benralizumab) can achieve near-complete depletion of eosinophils and improve clinical outcomes in hypereosinophilic syndrome (HES). In the randomized phase of the 20-patient trial, the
The company has initiated a novel TLR9 agonist project and announces a plan for a Phase I clinical trial. Clinical data shows that intratumoral delivery of TLR agonists in combination
The latest research news from the Nordic region
A Karolinska Institutet study on mice shows that the antibodies stabilise the plaque that accumulates on the artery walls, which reduces the risk of it rupturing and causing a blood
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.
Aishe A. Sarshad at the Sahlgrenska Academy, the University of Gothenburg, receives the L’Oréal-Unesco For Women in Science Prize in Sweden for having identified a new mechanism for regulating gene expression
We asked the new Swedish Minister for Higher Education and Research about what can be done to encourage and support women in science. Today is International Women’s Day and you
Researchers at the University of Turku have developed an immunotherapeutic antibody therapy that re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. In collaboration with Professor of Immunology
An international research team led by researchers at Karolinska Institutet report that bone growth in mice takes place in accordance with the same principles as when new cells are constantly